The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.
Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders. Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.
Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won't come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
The German drugmaker announced a partnership with Enleofen to develop the company's suite of preclinical antibodies targeting IL-11 in diseases like NASH.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
BI said it would continue to develop the drug, BI 1467335, in other diseases and remain committed to NASH overall. Shares of the Australian company from which it licensed the drug, Pharmaxis, fell more than 40%.
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal's lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
A panel discussion at the upcoming MedCity INVEST meeting in Chicago will look at real-world applications of blockchain technology in healthcare and biopharma.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
At the ongoing HIMSS conference in Orlando, Florida, the companies' Canadian divisions said their partnership would mark the technology's first use in clinical trials in Canada.
Market forecast rosy, though market in United States remains young.
Qualcomm Life also announced Tuesday that it would work with Boehringer Ingelheim Pharmaceuticals to develop a disposable, wireless connectivity module for the drug company's Respimat inhaler.
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.
Patients on Boehringer Ingelheim drugs for respiratory conditions have the option to enroll with certain health systems to get free access to inhalers embedded with Propeller Health sensors.